ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.

about

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.

Item

http://www.wikidata.org/entity/Q53692403

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

ATR kinase inhibitors NVP-BEZ2 ...... after systemic administration.

@en

ATR kinase inhibitors NVP-BEZ2 ...... after systemic administration.

@nl

type

Item

label

ATR kinase inhibitors NVP-BEZ2 ...... after systemic administration.

@en

ATR kinase inhibitors NVP-BEZ2 ...... after systemic administration.

@nl

prefLabel

ATR kinase inhibitors NVP-BEZ2 ...... after systemic administration.

@en

ATR kinase inhibitors NVP-BEZ2 ...... after systemic administration.

@nl

P1476

ATR kinase inhibitors NVP-BEZ2 ...... after systemic administration

@en

P2093

Aldo Profumo

http://www.w3.org/2001/XMLSchema#string

Daniela Marubbi

http://www.w3.org/2001/XMLSchema#string

Diana Marcello

http://www.w3.org/2001/XMLSchema#string

Jean Louis Ravetti

http://www.w3.org/2001/XMLSchema#string

P2860

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice

Overcoming therapeutic resistance in glioblastoma: the way forward

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Human neural stem cells: isolation, expansion and transplantation.

Origin of the U87MG glioma cell line: Good news and bad news.

Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.

P2888

s13014-018-1020-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13014-018-1020-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Daga

Guido Frosina

P577

2018-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103610193

http://www.w3.org/2001/XMLSchema#string

P698

29685176

http://www.w3.org/2001/XMLSchema#string

P932

5914052

http://www.w3.org/2001/XMLSchema#string